CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2014—Streck added markers to CD-Chex CD117 Plus, a commercially available positive procedural control for CD117, and now CD25 and CD71. CD-Chex 117 Plus eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, CD25, and CD71.
CD-Chex CD117 Plus was developed with characteristics similar to the abnormal peripheral blood leukocytes often found in a hematolymphoid neoplastic patient sample. The control possesses surface CD117, CD25, and CD71 that are detectable with fluorescent monoclonal antibodies by flow cytometry. Abnormal leukocytes are distinguishable from normal leukocytes on the basis of light scatter properties and a low level of CD45 expression.
CD-Chex CD117 Plus features 30-day open-vial stability and 90-day closed-vial stability. For research use only.
Streck, 800-843-0912